|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
|
DE69126301T2
(de)
|
1990-11-27 |
1998-01-02 |
Biogen, Inc., Cambridge, Mass. |
Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
|
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
|
AU2589095A
(en)
|
1994-05-16 |
1995-12-05 |
Washington University |
Cell membrane fusion composition and method
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
PL332875A1
(en)
|
1996-10-17 |
1999-10-25 |
Oxford Biomedica Ltd |
Retroviral vectors
|
|
EP0970227B1
(en)
|
1997-03-20 |
2008-01-09 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors
|
|
GB9720465D0
(en)
|
1997-09-25 |
1997-11-26 |
Oxford Biomedica Ltd |
Dual-virus vectors
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
ES2373406T3
(es)
|
1997-12-22 |
2012-02-03 |
Oxford Biomedica (Uk) Limited |
Vectores basados en el virus de la anemia infecciosa equina (vaie).
|
|
GB9803351D0
(en)
|
1998-02-17 |
1998-04-15 |
Oxford Biomedica Ltd |
Anti-viral vectors
|
|
FR2777909B1
(fr)
|
1998-04-24 |
2002-08-02 |
Pasteur Institut |
Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
|
|
JP2002524081A
(ja)
|
1998-09-04 |
2002-08-06 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
前立腺−特異的膜抗原に特異的な融合受容体およびその使用
|
|
WO2000023573A2
(en)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
|
|
GB0009760D0
(en)
|
2000-04-19 |
2000-06-07 |
Oxford Biomedica Ltd |
Method
|
|
US20020131960A1
(en)
|
2000-06-02 |
2002-09-19 |
Michel Sadelain |
Artificial antigen presenting cells and methods of use thereof
|
|
AU2001297703B2
(en)
|
2000-11-07 |
2006-10-19 |
City Of Hope |
CD19-specific redirected immune cells
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
AU2002302848C8
(en)
|
2001-06-14 |
2010-02-04 |
Cambridge Enterprise Limited |
CD4-specific antibody TRX1 and uses therefor
|
|
US7541443B2
(en)
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
|
CA2461351C
(en)
|
2001-09-26 |
2014-08-05 |
Ira H. Pastan |
Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
US7982011B2
(en)
|
2003-11-25 |
2011-07-19 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated anti-cd22 antibodies and immunoconjugates
|
|
US7842673B2
(en)
|
2003-12-17 |
2010-11-30 |
The Trustees Of Columbia University In The City Of New York |
Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA
|
|
WO2007109052A2
(en)
|
2006-03-16 |
2007-09-27 |
Genentech, Inc. |
Methods of treating lupus using cd4 antibodies
|
|
CA2682527C
(en)
|
2007-03-30 |
2017-07-11 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
|
TWI570135B
(zh)
|
2007-04-27 |
2017-02-11 |
建南德克公司 |
高效、穩定且非免疫抑制之抗－ｃｄ４抗體
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
EP4032552B1
(en)
|
2008-08-26 |
2023-10-04 |
City of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
EP2352764B1
(en)
|
2008-10-14 |
2018-03-28 |
Ablynx N.V. |
AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
|
|
WO2010074266A1
(ja)
|
2008-12-26 |
2010-07-01 |
協和発酵キリン株式会社 |
抗cd4抗体
|
|
EP2406284B9
(en)
|
2009-03-10 |
2017-03-01 |
Biogen MA Inc. |
Anti-bcma antibodies
|
|
US8911728B2
(en)
|
2010-05-21 |
2014-12-16 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins
|
|
EP2471543A1
(en)
|
2010-12-02 |
2012-07-04 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012113348A1
(zh)
|
2011-02-25 |
2012-08-30 |
厦门大学 |
抗cd4蛋白的单克隆抗体及其活性片段及用途
|
|
CN110200997A
(zh)
|
2011-03-23 |
2019-09-06 |
弗雷德哈钦森癌症研究中心 |
用于细胞免疫治疗的方法和组合物
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
WO2012156839A2
(en)
|
2011-05-19 |
2012-11-22 |
Ospedale San Raffaele S.R.L. |
New generation of splice-less lentiviral vectors for safer gene therapy applications
|
|
CA2833820C
(en)
|
2011-05-27 |
2019-10-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
WO2013040557A2
(en)
|
2011-09-16 |
2013-03-21 |
The Trustees Of The University Of Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
|
KR102134932B1
(ko)
|
2011-11-11 |
2020-07-17 |
프레드 헛친슨 켄서 리서치 센터 |
암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법
|
|
JP6850528B2
(ja)
|
2012-02-13 |
2021-03-31 |
シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート |
二重特異性キメラ抗原受容体およびその治療的使用
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
WO2013148327A1
(en)
|
2012-03-26 |
2013-10-03 |
The Regents Of The University Of California |
Nipah virus envelope psuedotyped lentiviruses and methods of their use
|
|
SG10201609210SA
(en)
|
2012-05-03 |
2016-12-29 |
Hutchinson Fred Cancer Res |
Enhanced affinity t cell receptors and methods for making the same
|
|
WO2013188870A2
(en)
|
2012-06-15 |
2013-12-19 |
Beth Israel Deaconess Medical Center, Inc. |
IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
|
|
CA2881981A1
(en)
|
2012-08-20 |
2014-02-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
AU2013327136A1
(en)
|
2012-10-02 |
2015-04-16 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
US9587022B2
(en)
|
2012-12-18 |
2017-03-07 |
The Rockefeller University |
Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
DK3166968T3
(da)
|
2014-05-02 |
2021-12-06 |
Univ Pennsylvania |
Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
WO2017058753A1
(en)
|
2015-09-28 |
2017-04-06 |
Trustees Of Dartmouth College |
Chimeric antigen receptor, regulatory cells and methods of use
|
|
EP3355937A4
(en)
|
2015-09-28 |
2019-04-17 |
Regents of the University of Minnesota |
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
|
|
TW201800459A
(zh)
|
2015-12-18 |
2018-01-01 |
富士軟片股份有限公司 |
近紅外線吸收組成物、近紅外線截止濾波器、近紅外線截止濾波器的製造方法、固體攝像元件、照相機模組及圖像顯示裝置
|
|
EP3235908A1
(en)
|
2016-04-21 |
2017-10-25 |
Ecole Normale Superieure De Lyon |
Methods for selectively modulating the activity of distinct subtypes of cells
|
|
JP7483373B2
(ja)
|
2016-07-29 |
2024-05-15 |
ジュノー セラピューティクス インコーポレイテッド |
複製可能ウイルスの存在または非存在を評価するための方法
|
|
EP4282877A3
(en)
|
2016-08-10 |
2024-02-21 |
Legend Biotech Ireland Limited |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
BR112019002734A2
(pt)
|
2016-08-13 |
2019-05-14 |
Ubi Ip Holdings |
tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart
|
|
WO2018156735A1
(en)
|
2017-02-22 |
2018-08-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibody for cancer immunotherapy
|
|
WO2018170096A1
(en)
|
2017-03-14 |
2018-09-20 |
Dualogics, Llc |
Use of a cd4/cd8 bispecific antibody for the treatment of diabetes
|
|
AU2018269194B2
(en)
|
2017-05-15 |
2025-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
|
US20200138865A1
(en)
|
2017-06-30 |
2020-05-07 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Anti-b-cell maturation antigen chimeric antigen receptors with human domains
|
|
AU2019214183B2
(en)
|
2018-02-01 |
2022-04-07 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
|
|
CN116082518A
(zh)
|
2018-02-01 |
2023-05-09 |
南京驯鹿生物技术股份有限公司 |
一种结合bcma的嵌合抗原受体（car）及其应用
|
|
US11266690B2
(en)
|
2018-02-01 |
2022-03-08 |
Nanjing Iaso Biotherapeutics Co., Ltd. |
Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
|
|
KR102721494B1
(ko)
|
2018-04-17 |
2024-10-24 |
국립암센터 |
고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도
|
|
AU2019269593A1
(en)
|
2018-05-15 |
2020-11-26 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions and uses thereof
|
|
WO2019236684A1
(en)
|
2018-06-08 |
2019-12-12 |
Imaginab, Inc. |
Antigen binding constructs to cd4
|
|
WO2019246514A1
(en)
|
2018-06-21 |
2019-12-26 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-psma x anti-cd28 antibodies and uses thereof
|
|
EP3820509A1
(en)
|
2018-07-09 |
2021-05-19 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions and uses thereof
|
|
EP3820903A1
(en)
|
2018-07-12 |
2021-05-19 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Affinity matured cd22-specific monoclonal antibody and uses thereof
|
|
CA3115679A1
(en)
|
2018-10-09 |
2020-04-16 |
Sanofi |
Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
|
|
WO2020102503A2
(en)
|
2018-11-14 |
2020-05-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for t cell delivery
|
|
SG11202105079QA
(en)
|
2018-11-14 |
2021-06-29 |
Flagship Pioneering Innovations V Inc |
Fusosome compositions for cns delivery
|
|
EP3880832A1
(en)
|
2018-11-14 |
2021-09-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for hematopoietic stem cell delivery
|
|
MA54540A
(fr)
|
2018-12-19 |
2021-10-27 |
Regeneron Pharma |
Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
|
|
US11453721B2
(en)
|
2018-12-19 |
2022-09-27 |
Regeneran Pharmaceuticals, Inc. |
Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
|
|
TWI861039B
(zh)
|
2018-12-21 |
2024-11-11 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之促效cd28抗原結合分子
|
|
JP2022513495A
(ja)
|
2018-12-21 |
2022-02-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子
|
|
WO2020198009A1
(en)
|
2019-03-22 |
2020-10-01 |
Regeneron Pharmaceuticals, Inc. |
EGFR x CD28 MULTISPECIFIC ANTIBODIES
|
|
US11613576B2
(en)
|
2019-04-09 |
2023-03-28 |
Sanofi |
Trispecific binding proteins, methods, and uses thereof
|
|
CN113840912A
(zh)
|
2019-05-16 |
2021-12-24 |
南京传奇生物科技有限公司 |
包含识别分子的工程化免疫细胞
|